We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JPM:NYSEJP Morgan Chase & Co. Analysis

Data as of 2026-03-09 - not real-time

$285.25

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

JPMorgan Chase shares are trading at $285.25, notably below the 20‑day SMA of 303.07, the 50‑day SMA of 310.53 and the 200‑day SMA of 300.23, indicating short‑term weakness. Technical signals are mixed: the MACD is bearish (line –5.23 vs signal –3.60) and the histogram is negative, yet the RSI of 33.2 suggests the stock is oversold and may be primed for a bounce. Valuation appears attractive with a trailing P/E of 14.24 versus the industry average of 17.20 and a forward P/E of 12.14, supporting an estimated upside of roughly 21% based on analyst median targets around $345. The dividend yield of 2.07% and a modest payout ratio of 29% point to a sustainable income stream. Recent analyst activity has been positive, with Baird and HSBC moving ratings toward neutral/hold and setting price targets between $280 and $319, reflecting confidence despite a recent earnings miss. However, volatility remains elevated at 27% over the past 30 days and beta is near 1, underscoring market sensitivity.
The bank’s fundamentals remain solid: ROE stands at 16.1%, operating margin at 41%, and cash balances of $1.29 trillion comfortably exceed debt of $1.03 trillion. The diversified business model across consumer banking, investment banking and wealth management provides resilience, while the dividend and strong balance sheet support a long‑term bullish case. Given the blend of technical oversold conditions, valuation headroom and robust fundamentals, the stock is positioned for a potential rebound in the medium term, with continued upside potential as interest rates stabilize and earnings momentum improves.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Oversold RSI indicating potential short‑term bounce
  • Bearish MACD and price below key moving averages
  • Support level near $280 providing downside cushion

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Valuation gap (P/E 14.2 vs industry 17.2)
  • Analyst price targets implying ~20% upside
  • Sustainable dividend yield of 2.07%

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong ROE and diversified revenue streams
  • Robust balance sheet with cash exceeding debt
  • Consistent dividend policy with low payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth2.50%
Profit Margin33.91%
P/E Ratio14.2
ROE16.13%
ROA1.35%
P/B Ratio2.2
Op. Cash Flow$-147781992448
Industry P/E17.2

Technical Analysis

TrendNeutral
RSI33.2
Support$280.45
Resistance$326.40
MA 20$303.07
MA 50$310.53
MA 200$300.23
MACDBearish
VolumeStable
Fear & Greed Index100

Valuation

Target Price$344.78
Upside/Downside20.87%
GradeUndervalued
TypeValue
Dividend Yield2.07%

Risk Assessment

Beta0.98
Volatility27.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.